Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. (HMTXF) generates news that spans biotechnology, clinical development, and commercialization of autologous stem cell therapy for ischemic disease. The company’s updates frequently center on its VesCell (ACP-01) platform, a patient-derived blood-based stem cell therapy that Hemostemix reports has been studied in multiple clinical trials for peripheral arterial disease, chronic limb threatening ischemia, cardiomyopathies, congestive heart failure, angina, total body ischemia, and vascular dementia.
Investors following HMTXF news can expect regular announcements on clinical milestones, regulatory interactions, and physician-led initiatives. Hemostemix has reported the completion of a Phase II clinical trial in chronic limb threatening ischemia, publication of results in peer-reviewed journals, and presentations of long-term outcomes such as limb preservation, wound healing, and mortality data in severe ischemic patient populations. News items also describe plans for a basket protocol Phase I trial in ischemia-related conditions and a scheduled FDA Pre-IND meeting to review the company’s proposed trial design and regulatory pathway.
Corporate developments are another recurring theme in Hemostemix’s news flow. The company issues releases on non-brokered private placements, stock option grants, and capital raises intended to fund regulatory, clinical, and commercialization activities for ACP-01. It also reports on strategic moves such as a clinic roll-up strategy, including letters of intent to acquire cardiology practices that have experience treating patients with ACP-01, as well as the build-out of patient care and clinical operations roles.
Sector-specific coverage includes Hemostemix’s participation in conferences focused on wound healing, diabetic limb salvage, and regenerative medicine, where the company highlights its CLTI and cardiovascular data. For readers tracking HMTXF, this news page offers a consolidated view of scientific, regulatory, financial, and operational updates related to Hemostemix’s autologous stem cell therapy platform.
Hemostemix (OTCQB: HMTXF) announced a non‑brokered private placement of up to $700,000 with a lead order of $330,000 on October 7, 2025. Units priced at $0.11 include one common share and one warrant exercisable at $0.15 for two years from closing.
Warrants include an accelerator: if the 10‑day weighted average closing price exceeds $0.185 after four months, expiry can be accelerated to 30 days after notice. A company director is participating, triggering related‑party disclosures; the company is relying on MI 61‑101 exemptions for valuation and minority approval. Proceeds are allocated to general working capital, including marketing and sales of VesCell™.
Hemostemix (OTCQB: HMTXF) has filed FDA Pre-IND Application 1517 for a basket protocol Phase I clinical trial of its lead therapy ACP-01 (VesCell™). The trial aims to evaluate safety, feasibility, and early efficacy of ACP-01 across multiple conditions including vascular dementia, peripheral arterial disease, angina, cardiomyopathy, and congestive heart failure.
The company plans to integrate real-world evidence from Florida, where ACP-01 is legally available under SB 1768, to support IND advancement and expedited regulatory designations. Hemostemix has completed 498 safe treatments to date and has 11 peer-reviewed publications demonstrating safety and efficacy.
Hemostemix (OTCQB: HMTXF), a leading autologous stem cell therapy company, announced that CEO Thomas Smeenk will present at the Life Science Investor Forum on September 18, 2025, at 12:00 p.m. ET. The company's flagship product, VesCell™ (ACP-01), treats various cardiovascular conditions including peripheral arterial disease and chronic limb threatening ischemia.
The company has demonstrated strong clinical credentials with 498 successful treatments and 11 peer-reviewed publications confirming safety and efficacy. Following Florida Senate Bill 1768's passage, Hemostemix can now offer treatments to no-option patients in Florida, marking a significant milestone in commercialization.
Hemostemix (OTCQB: HMTXF) has announced the upcoming presentation of significant clinical data for its VesCell™ (ACP-01) therapy in treating severe angina. The study demonstrated remarkable improvements in patients with chronic stable angina who had exhausted traditional treatment options.
Key clinical findings include: 24% increase in six-minute walk distance (from 333.65 to 414.95 meters), 26% improvement in exercise capacity (from 5.62 to 7.09 METs), and a 45% reduction in heart muscle perfusion defects. The Canadian Cardiovascular Society angina score improved significantly from 2.1 to 1.05, indicating substantial pain relief.
The company plans to offer this treatment in Florida under SB 1768, using the revenue and real-world data to fund a future double-blind randomized clinical trial for global approval.
Hemostemix (OTCQB:HMTXF), a leading autologous stem cell therapy company, has received TSXV approval to settle CDN$400,000 of debt through the issuance of 2,000,000 common shares at $0.20 per share.
The Settlement Shares will be subject to a four-month statutory hold period and require TSXV acceptance. The company confirms this debt settlement will not create a new control person, and no finder's fees will be paid. Hemostemix offers VesCell™ (ACP-01) therapy in Florida under SB 1768 for various cardiovascular and ischemic conditions.
Hemostemix (OTCQB: HMTXF), a leading autologous stem cell therapy company, has announced a non-brokered private placement of $280,594 at $0.125 per share. The company will issue 2,244,752 shares, subject to TSX Venture Exchange approval.
The company's flagship product, VesCell™ (ACP-01), treats various conditions including peripheral arterial disease, chronic limb threatening ischemia, and various cardiac conditions in Florida under SB 1768. The proceeds will support general working capital, operational expenses, and business development activities.
Hemostemix (OTCQB: HMTXF) has announced the launch of its upgraded HubSpot-powered corporate websites, marking a significant advancement in its digital marketing capabilities. The company, which offers VesCell™ (ACP-01) stem cell therapy for various conditions including peripheral arterial disease and heart conditions, has transformed its static websites into an integrated marketing and CRM sales platform.
The new platform features AI-driven patient engagement, HIPAA-compliant portals, and automated administrative workflows. Key improvements include streamlined lead generation, efficient patient intake, and targeted clinical partner outreach in Florida, where the therapy is available under SB 1768 for patients with life-threatening conditions who have exhausted standard treatment options.
The company expects to achieve 20% administrative cost savings and improved patient access through multilingual support and AI-powered capabilities. The platform will support Hemostemix's global expansion plans while maintaining regulatory compliance.
Hemostemix (OTCQB: HMTXF) has launched VesCell.Health, an educational website in Florida to support the rollout of its VesCell™ autologous stem cell therapy. The launch follows Florida's SB 1768 legislation, which now allows the use of VesCell™ for patients with life-threatening conditions who have exhausted standard treatment options.
The website serves as an educational platform explaining the therapy's benefits and includes 11 peer-reviewed publications documenting VesCell's safety and efficacy across seven clinical trials. The therapy targets multiple conditions including peripheral arterial disease, chronic limb threatening ischemia, angina, and various forms of cardiomyopathy.
Hemostemix (OTCQB: HMTXF) highlighted a remarkable patient success story of Howie Lindeman, who has gained over 17 years of life following a VesCell™ (ACP-01) treatment in 2008. Howie, a six-time Grammy Award-winning producer, received the autologous stem cell therapy for ischemic cardiomyopathy, resulting in his ejection fraction nearly doubling from the low 20% range to the 40% range.
The company's VesCell™ therapy, now authorized under Florida's SB 1768 for patients with life-threatening conditions, has treated 498 patients across seven clinical studies, with results documented in 11 peer-reviewed publications. Studies have shown up to a 47.1% increase in ejection fraction in dilated cardiomyopathy patients.
Hemostemix (OTCQB: HMTXF) has partnered with MedLoanFinancing to provide financing options for its VesCell™ (ACP-01) stem cell therapy treatments in Florida. The financing allows patients to access up to $50,000 in credit through monthly payment plans, making the treatment more accessible under Florida's SB 1768 law.
The company is presenting significant clinical trial results to medical facilities in Naples and Boca Raton. The trials showed that ulcer size in treated patients decreased from 1.46 cm² to 0.48 mm² within 3 months (p = 0.01), while the placebo group showed no significant improvement (p < 0.54).
FAQ
What is the current stock price of Hemostemix (HMTXF)?
What is the market cap of Hemostemix (HMTXF)?
